A phase I-II trial of Ispinesib, a kinesin spindle protein inhibitor, dosed every two weeks in patients with locally advanced or metastatic breast cancer previously untreated with chemotherapy for metastatic disease or recurrence.

被引：0
|
作者：
Gomez, H.
Castaneda, C.
Philco, M.
Pimentel, P.
Falcon, S.
Escandon, R.
Saikali, K.
Conlan, M.
Seroogy, J.
Wolff, A.
机构：
[1] Inst Nacl Enfermedades Neoplasicas, Lima, Peru
[2] Hosp Nacl Alberto Sabogal Sologuren, Lima, Peru
[3] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[4] Cytokinet Inc, San Francisco, CA USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：199S / 200S
页数：2
相关论文
共 50 条
  • [31] Results of a phase II trial of Herceptin® plus Xeloda® in patients with previously untreated HER2-positive metastatic breast cancer
    Xu, L
    Song, S
    Zhu, J
    Luo, R
    Lil, L
    Jiao, S
    Pan, H
    Tao, M
    Su, Y
    Liu, D
    Chen, L
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S129
  • [32] Phase I/II trial of pembrolizumab in combination with binimetinib in unresectable locally advanced or metastatic triple negative breast cancer.
    Chumsri, Saranya
    Polley, Mei-Yin
    Anderson, Sarah L.
    O'Sullivan, Ciara Catherine Maria
    Colon-Otero, Gerardo
    Knutson, Keith L.
    Thompson, E. Aubrey
    Moreno-Aspitia, Alvaro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [33] Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: A phase I-II trial
    Stathopoulos, George P.
    Dimitroulis, John
    Toubis, Michael
    Katis, Costas
    Karaindros, Dimitris
    Stathopoulos, John
    Koutandos, John
    LUNG CANCER, 2007, 57 (01) : 66 - 71
  • [34] Iphosphamide(I) plus vinorelbine (VRB) in metastatic breast cancer patients previously treated with combination chemotherapy. Preliminary results of a phase II trial
    Lobo, F
    Mendez, M
    Barnadas, A
    Busquier, I
    Lizon, J
    Provencio, M
    Albistur, J
    Martinez, P
    Sanchez, MJ
    Constela, M
    Diaz, FJ
    de Mostoles, HG
    Pujol, HGTI
    de Castellon, HG
    San Juan, H
    de Hierro, CP
    ANNALS OF ONCOLOGY, 1998, 9 : 28 - 28
  • [35] Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer
    O'Shaughnessy, Joyce A.
    Pluenneke, Robert
    Sternberg, Jack
    Khandelwal, Pankaj
    Ilegbodu, Des
    Asmar, Lina
    CLINICAL BREAST CANCER, 2006, 6 (06) : 505 - 510
  • [36] Phase I/II and pharmacokinetic study of combination chemotherapy with S-1 and oxaliplatin in patients with previously untreated metastatic or recurrent gastric cancer
    Park, I.
    Lee, J.
    Ryu, M.
    Chang, H.
    Kim, T.
    Sym, S.
    Lee, S.
    Jang, G.
    Bae, K.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease:: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001
    Hejna, Michael
    Raderer, Markus
    Zacherl, Johannes
    Ba-Ssalamah, Ahmed
    Puespoek, Andreas
    Schmidinger, Manuela
    Pluschnig, Ursula
    Brodowicz, Thomas
    Zielinski, Christoph C.
    ANTI-CANCER DRUGS, 2008, 19 (05) : 535 - 539
  • [38] Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
    Campone, M.
    Bondarenko, I.
    Brincat, S.
    Hotko, Y.
    Munster, P. N.
    Chmielowska, E.
    Fumoleau, P.
    Ward, R.
    Bardy-Bouxin, N.
    Leip, E.
    Turnbull, K.
    Zacharchuk, C.
    Epstein, R. J.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 610 - 617
  • [39] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Jaime Feliu
    Mónica Jorge Fernández
    Teresa Macarulla
    Bartomeu Massuti
    Ana Albero
    José Federico González González
    Guillermo Quintero-Aldana
    Juan Ignacio Delgado-Mingorance
    Ana Fernández Montes
    Carmen García Piernavieja
    Manuel Valladares-Ayerbes
    Ana María López Muñoz
    Rebeca Mondéjar Solís
    Pilar Vicente
    Esther Casado Gonzalez
    Irene González Cebrián
    Guillermo López-Vivanco
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 543 - 553
  • [40] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Feliu, Jaime
    Jorge Fernandez, Monica
    Macarulla, Teresa
    Massuti, Bartomeu
    Albero, Ana
    Gonzalez Gonzalez, Jose Federico
    Quintero-Aldana, Guillermo
    Ignacio Delgado-Mingorance, Juan
    Fernandez Montes, Ana
    Garcia Piernavieja, Carmen
    Valladares-Ayerbes, Manuel
    Lopez Munoz, Ana Maria
    Mondejar Solis, Rebeca
    Vicente, Pilar
    Casado Gonzalez, Esther
    Gonzalez Cebrian, Irene
    Lopez-Vivanco, Guillermo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (04) : 543 - 553
12345